Protocol: H8H-MC-LAHX
A Phase 1, Open-Label, Single-Dose Pharmacokinetic Study of Lasmiditan in Pediatric Patients 
with Migraine
[STUDY_ID_REMOVED]   
Approval Date: 29-Mar-2019 
H8H-MC-LAHX Clinical Pharmacology Protocol Page 1
LY573144A Phase 1, Open -Label, Single -Dose Pharmacokinetic 
Study  of Lasmiditan in Pediatric Patien ts with Migraine
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_72118] (LY573144 ), unless such persons are bound by a confidentiality agreement with 
Eli Lilly and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commerciall y confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the [LOCATION_002], this document is patient to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
Lasmiditan (LY573144 )
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Clinical Pharmacology Protocol Electronically Signed and Approved by [CONTACT_72128].
Approval Date: 29-Mar-[ADDRESS_87835] ivities.................................................................................................. 10
2. Introduction ...................................................................................................................... 15
2.1. Study  Rati onale ............................................................................................................ 15
2.2. Background .................................................................................................................. 15
2.3. Benefit/Risk Asse ssment .............................................................................................. [ADDRESS_87836] yle and/or Dietary Considerations ........................................................................ 26
5.3.1. Meals and Dietary  Restri ctions............................................................................. 26
5.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 26
5.4. Screen Failures ............................................................................................................. 26
6. Treatment .......................................................................................................................... 28
6.1. Treatment Administered ............................................................................................... 28
6.1.1. Packaging and Labeling ....................................................................................... 28
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................... 29
6.3. Measures to Minimize Bias:  Rando mizat ion and Blinding ........................................... [ADDRESS_87837] to Follow -Up........................................................................................... 32
8. Study  Assessments and Procedures ................................................................................... 33
8.1. Efficacy Assessments ................................................................................................... 33
8.2. Safety Assessments ...................................................................................................... 33
8.2.1. Physical Examinat ion........................................................................................... 33
8.2.2. Vital Signs
........................................................................................................... 33
8.2.3. Electrocardiograms .............................................................................................. 34
8.2.4. Clinical Safety  Laboratory  Assessments ............................................................... 34
[IP_ADDRESS]. Hepati c Safet y Moni toring .............................................................................. 35
8.2.5. Suicidal  Ideat ion and Behavior Risk Monitoring .................................................. 35
[IP_ADDRESS]. C-SSRS .......................................................................................................... 35
[IP_ADDRESS]. Columbia -Suicide Severit y Rating Scale –Child Version ............................... 36
[IP_ADDRESS]. Self-Harm and Follow -up Suppl ement Form s................................................. [ADDRESS_87838] ....................................................................................... 41
8.3.9. Com plaint Handling ............................................................................................. 41
8.4. Treatment of Overdose .................................................................................................41
8.5. Pharmacokinet ics......................................................................................................... 41
8.5.1. Bioanalysis ........................................................................................................... 42
H8H-MC-LAHX Clinical Pharmacology Protocol Page 4
LY5731448.6. Pharmacodynamics ...................................................................................................... 42
8.7. Genet ics....................................................................................................................... 42
8.8. Biomarkers ................................................................................................................... 42
8.9. Heal th Economics ........................................................................................................ 42
9. Statistical Considerations and Data Analysis ..................................................................... 43
9.1. Statistical Hypotheses .................................................................................................. 43
9.2. Sample Si ze Determinat ion.......................................................................................... 43
9.3. Popul ations for Analyses .............................................................................................. 43
9.3.1. P atient Disposi tion............................................................................................... 43
9.3.2. Patient Characteri stics.......................................................................................... 43
9.4. Statistical Analyses ...................................................................................................... 43
9.4.1. Safety Analyses .................................................................................................... 44
[IP_ADDRESS]. Clinical Evaluation of Safet y.......................................................................... 44
[IP_ADDRESS]. Statistical Evaluat ion of Safet y....................................................................... 44
9.4.2. Pharmacokinet ic Analyses .................................................................................... 44
[IP_ADDRESS]. Pharmacokinet ic Parameter Estimat ion........................................................... 44
9.4.3. Data Review during the Study .............................................................................. 45
9.5. Interim Analyses .......................................................................................................... 45
9.6. Data Monitoring Committee ......................................................................................... 45
10. Supporting Documentation and Operational Considerations .............................................. 46
10.1. Regulatory , Ethical , and Study  Oversight Consi derati ons............................................. 46
10.1.1. Regulatory  and Ethi cal Considerat ions.................................................................46
10.1.2. Inform ed Consent .................................................................................................46
10.1.3. Data Protection .................................................................................................... 47
10.1.4. Protocol  Signatures .............................................................................................. 47
10.1.5. Final Report Signature ......................................................................................... 47
10.1.6. Data Qualit y Assurance ........................................................................................ 47
10.1.7. Study  and Si te Cl osure ......................................................................................... 49
[IP_ADDRESS]. Discontinuati on of  Study  Sites........................................................................ 49
[IP_ADDRESS]. Discontinuati on of  the Study ........................................................................... [ADDRESS_87839] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 52
Appendix 2. Clinical Laboratory  Tests ........................................................................ 55
Appendix 3. Liver Safety :  Suggested Acti ons and Foll ow-Up Assessments ............... 57
H8H-MC-LAHX Clinical Pharmacology Protocol Page 8
LY5731441.Protocol Summary
1.1. Protocol Synopsis
Title of Study:
A Phase 1, Open -Label, Single -Dose Pharmacokinetic Study of Lasmiditan in Pediatric Patients with Migraine .
Rationale: 
This study is being conducted to determine the pharmacokinetic s(PK) ,safety ,and tolerability of lasmiditan in
pediatric patients with migraine following a single oral do se.
Objectives /Endpoints:
Objectives Endpoints
Primary
To assess the single -dose pharmacokinetics of 
lasmiditan in pediatric migraine patientsPharmacokinetic parameters including:
Maximum observed drug concentration (C max)
Time to reach Cmax(tmax)
Area under the concentration -versus -time curve (AUC) 
from time zero to infinity (AUC [0-])
AUC from time zero to the time t, where t is the last 
time point with measurable concentration (AUC [0-tlast])
Secondary
To assess the safety and tolerability of a single dose 
of lasmiditan in pediatric migraine patientsSummary of: 
SAEs
AEs
ECG
vital signs
Exploratory
To assess the safety, tolerability ,and 
pharmacokinetics of lasmiditan in Japanese 
pediatric migraine patientsPharmacokinetic parameters including:
Cmax
tmax
AUC [0-]
AUC [0-tlast]
Summary of adverse events, SAE s, ECG, and vital signs.
Abbreviations: AE = adverse event; ECG = electrocardiogram; SAE = serious adverse event.
Summary of Study Design
This is a Phase 1, multicenter, open -label, single -dose study to determine the PK ,safety ,and tolerability of 
lasmiditan in pediatric patients with a diagn osisof migraine .
Treatment Arms and Planned Duration
Two cohorts will be evaluated concurrently :
Primary  Cohort 1 : 15 kg to ≤40 kg
Secondary Cohort 2 : >40 kg to ≤55kg
The planned doses for Cohorts 1 and 2 are 100 mg and 200 mg, respectively.
Visit 1 : Screening
H8H-MC-LAHX Clinical Pharmacology Protocol Page 9
LY573144All patients arescreened to determine if they are eligible to participate in the study.
Screening will occur up to 28 days to 3 days prior to lasmiditan dosing.
Visits 2–3: Dosing and PK Assessment s
Day 1(Visit 2)
Patients arrive at the Clinical Research Unit(CRU) for assessments prior to dosing .
Patients receive the single lasmiditan dose .
Patients can go home after the 12-h our assessments.  Patients may be offered the opportunity to spend the 
night depending on CRU capabilities .
Day 2(Visit 3)
Patient assessments are done at the CRU approximately 24 hours after dosing .
Visit 4/801
Visit 4/801 will occur approximately 14 days after dosing .
Visit 801 –Patients in Japan and those who will not proceed to the 3-month addendum will complete assessments 
according to Visit 801 in the Schedule of Activities.
Visit 4 –Patients continuing to the addendum will complete assessments according to the Schedule of Activities in 
the addendum.
Number of Patient s
Cohort 1
Approxima tely 13 patients may  be enrolled to obtain 11 patients with evaluable PK data.
Cohort 2
Approximately 8 patients may be enrolled to obtain 6 patients with evaluable PK data.
Statistical Analysis:
Safety parameters that will be assessed include :
adverse eve ntsincluding clinically significant electrocardiogram s
serious adverse events
vital signs
Columbia -Suicide Severity Rating Scale ( C-SSRS )assessments
Cognition, as assessed by [CONTACT_80496], and listed and summarized using descriptive statistics.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 10
LY5731441.2. Schema
Abbreviation:  PK = pharmacokinetic.
1.3. Schedule of ActivitiesVisit 1
ScreeningVisit 2
PK and Saf ety
AssessmentsVisit 3
24 hour 
AssessmentsVisit 801
Follow -up
Addendum 
VisitsParticipants in 
Japan or those 
who will not 
proceed to 
addendum
Participants 
proceeding to 
addendum
H8H-MC-LAHX Clinical Pharmacology Protocol Page 11
LY573144Table LAHX.1. Schedule of A ctivities for Patients Participating in the Open -Label PK Study
Study Period (SP)SP I
ScreeningSP II
PK Assessment/SafetyEDaSP III Notes
Visit 1 2 3 4/801b
Time from 
Lasmiditan Dose 
(hr)Predose Dose 0.5 11.5 234812 24
Study Day -28 to -3 Day 1 Day 
2Day 
14±3
Assessments and Procedures
Informed 
consent/AssentX
Inclusion/exclusion 
criteria reviewX X
Demographics X
Medical history X X
Substance use 
historyX X Alcohol andtobacco use for patients aged 
>10 years
Concomitant 
medicationsX X X X X X At screening, previous and ongoing 
migraine treatments will be collected.
Physical 
examinationX X X X
Targeted neurologic 
examinationX X X X
Height X Height will be measured using a 
stadiometer andmeasured in triplicate .
Weight X X X Weight will be measured once.
Menstrual status X
12-lead ECG
(single)X X X ECG procedure occurs prior to blood 
draws and dosing. Patients must be supi[INVESTIGATOR_31146] 5 minutes before collection and 
remain supi[INVESTIGATOR_80482] 
H8H-MC-LAHX Clinical Pharmacology Protocol Page 12
LY573144Study Period (SP)SP I
ScreeningSP II
PK Assessment/SafetyEDaSP III Notes
Visit 1 2 3 4/801b
Time from 
Lasmiditan Dose 
(hr)Predose Dose 0.5 11.5 234812 24
Study Day -28 to -3 Day 1 Day 
2Day 
14±3
procedure .
Vital signs
  Blood pressure and
pulseX X X X X X X X X At screening –single measurement.
All other time points –triplicate
measurements, and prior to blood draws 
and lasmiditan administration.  Blood 
pressure measurements will be taken by [CONTACT_80497] (if calibration is 
required) machine.
Orthostatic Vital 
SignsX X X X X
Temperature X X
Adverse events X X X X X
Lasmiditan d osing X
Clinical Laboratory Tests and Sampling
Hematology X X X
Clinical chemistry X X X
Gonadal ho rmones X Estradiol (for females) or testosterone (for 
males) will be coll ected in patients aged 8 
to <18 years, to assess pubertal status.
Urinaly sis X
Urine drug screen X X For patients aged >10 years .
H8H-MC-LAHX Clinical Pharmacology Protocol Page 13
LY573144Study Period (SP)SP I
ScreeningSP II
PK Assessment/SafetyEDaSP III Notes
Visit 1 2 3 4/801b
Time from 
Lasmiditan Dose 
(hr)Predose Dose 0.5 11.5 234812 24
Study Day -28 to -3 Day 1 Day 
2Day 
14±[ADDRESS_87840] is not needed.
PK blood sample X X X X X X X X X An indwelling catheter is required for 
blood collection on Day 1 .  See Notes for 
time windows and order of procedures.
Scale sand Questionnaire s
C-SSRS
Children’s version
SHSF, SHFUX X X X X Suicidal ideation and behavior subscales 
excerpt –Adapted for the assessment of 11 
preferred ideation and behavior categories. 
The C -SSRS will be scored only in patients 
≥7 years old. The Self -Harm Follow -Up 
Form is required only if triggered by [CONTACT_80498]-Harm Supplement Form.
Cogstate Pediatric 
Brief BatteryX X X X X X Participants will be instructed on use at 
screening .
H8H-MC-LAHX Clinical Pharmacology Protocol Page 14
LY573144Abbreviations:  C-SSRS = Columbia -Suicide Severity Rating Scale; ECG = electrocardiogram ; ED = early discontinuation; PK = pharmacokinetic; SHFU = 
Self-Harm Follow -Up form; SHSF = Self-Harm Supplement form .
aEarly discontinuation procedures should be conducted if a patient discontinues from the study before follow -up visit.
bVisit 801 –For patients in Japan and those who will not proceed to the 3 -month addendum.  Visit 4 –Patients continuing to the addendum will complete 
assessments according to the Schedule of Activities in the addendum.
Note:  If multiple procedur es take place at the same time point, the following order of the procedure should be use d: 
ECG, vital signs and orthostatic vital signs, and venipuncture .
Where venipuncture and other procedures take place at the same time point, the following time window s for obtaining blood samples should be maintained:  
>0 to 2 hours postdose: ±5minutes 
2.5 to 6 hours postdose: ±10minutes 
>6 to 12 hours postdose: ±20minutes 
12hours postdose: ±30minutes
24 hours postdose: ±60minutes .
Where repeats of vital signs measurements are required, repeats should be performed after venipuncture.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 15
LY5731442.Introduction
2.1. Study Rationale
This study  is being conducted to determine the pharm acokinet ics (PK),safety ,and tol erabili ty of 
lasmiditan in pediatric migraine patients following a single oral  dose of lasmiditan.
This study  is part of a pediatric (6to 18years) clinical program for lasmidi tan. The data from 
this study  will be used to inform dose sel ection in subsequent clinical studies intended to provide 
pi[INVESTIGATOR_80483] y data to support use of lasmiditan for acute treatm ent of  migraine in 
children and ado lescents.
This study  will also include Japanese pediatric pat ients to facilitate lasmiditan pediatri c clinical 
development in Japan .
2.2. Background
Lasmiditan is being developed as a novel therapy for the acute treatment of migraine.   
Lasmiditan is a high -affini ty, centrally penetrant, select ive human serotonin 1F (5- HT 1F) receptor 
agonist that exerts its therapeutic effects in th e treatm ent of migraine by  [CONTACT_80499], including the trigeminal nerve.   Lasmiditan is structurally 
and mechanist ically dist inct fro m other approaches for the acute treatment of migraine, such as 
triptans, a nd lacks the vasoconstrict ive effects of triptans that result from 5 -HT 1Bactivity.
Across clinical trials in adults, lasmiditan was generally well tolerated and the majorit y of 
adverse events (AEs) wer emild to moderate, w ith a duration of 1 to 5 hours for the commo n 
treatm ent-emergent adverse events (TEAEs).  Lasmiditan use is associated with neurologic 
TEAEs, with the most commo n being dizziness, paresthesia, somno lence, fatigue, nausea, 
hypoesthesia, and muscle weakness.   In a variet y of analyses ofPhase [ADDRESS_87841] bothersome symptom s.  A consistent dose –response relat ionship was 
observed, with pat ients in higher dose groups having a greater likelihood of response across 
multiple efficacy endpo ints. Based on these data in adults with migraine, l asmidi tan m ay 
provi de therapeutic benefit to children an d adolescents from 6 to <18 y ears of age with migraine .
A population pharmacokinet ic(popPK) analysis of adul t PK data following oral  administrati on
indicates that lasmiditan israpi[INVESTIGATOR_80484] a median time to reach maximum observed 
drug concentrati on (t max) of 1.8 hours and is eliminated wi th a geom etric mean value of 5.7 hours 
for terminal half -
life.  Over the clinical dose range of 50 to 200 mg, l asmidi tan exposure 
generally increase slinear lywith dose.   The interindividual variability of lasmidi tan maximum 
observed drug concentration ( Cmax)and area under the concentration -versus -time curve ( AUC )
are43% and 39%, respectively, based on the popPK analysis.  The covariates of body weight, age 
[elderly vs .nonelderly], and population [healthy vs .patient] were statistically significant in the 
H8H-MC-LAHX Clinical Pharmacology Protocol Page 16
LY573144popPK model, but the magnitude of these effects was within the PK variability and therefore not 
considered to be clinically relevant over the range of covariate values in the population.
2.3. Benefit/Risk Assessment
This is an open -label study  in which all pediatric patients will receive a single dose of lasmiditan . 
Parti cipants in the [LOCATION_002] ( US)will have the opportunit y to parti cipate in an open -label, [ADDRESS_87842] the opportuni ty to parti cipate in an open -label, 12 -month long-term 
safet y study (Study  H8H -MC-LAHW )when it i s available .
As a centrall y penetrant and neurally act ive drug, lasmiditan use is associated with neuro logic 
TEAEs, with the most commo n being dizziness, paresthesia, somno lence, fatigue, nausea, 
hypoesthesia, and muscle weakness.  It is generally well tolerated, and the vast major ity of 
events are mild to moderate and self- limit ing.
More i nform ation about the known and expected benefits, risks, serious adverse events (SAEs) ,
and reasonably ant icipated AEs of lasmidi tanmaybe found in the Invest igator ’s Brochure (IB).
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87843] ives and endpo ints of the study .
Table LAHX.2. Objectives and Endpoints
Objectives Endpoints
Primary
To assess the single -dose pharmacokinetics of 
lasmiditan in pediatric migraine patientsPharmacokinetic parameters including:
Maximum observed drug concentration (C max)
Time to reach Cmax(tmax)
Area under the concentration -versus -time curve 
(AUC) from time zero to infinity (AUC [0-])
AUC from time zero to the time t, where t is the 
last time point with measurable concentration 
(AUC [0-tlast]).
Secondary
To assess the safety and tolerability of a single dose of 
lasmiditan in pediatric migraine patientsSummary of :
SAEs
AEs
ECG
vital signs
Exploratory
To assess the safety, tolerability ,and pharmacokinetics 
of lasmiditan in Japanese pediatric migraine patientsPharmacokinetic parameters including:
Cmax
tmax
AUC [0-]
AUC [0-tlast]
Summary of adverse events, SAE s, and vital signs .
Abbreviations:  AE = adverse event; ECG = electrocardiogram; SAE = serious adverse event.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 18
LY5731444.Study  Design
4.1. OverallDesign
This is a Phase 1, multicenter, open -label, single -dose study  to determine the PK , safety,and 
tolerabilit y of lasmiditan in pediatric patient s with a diagnosis of migraine.
Two cohorts will be evaluated concurrently :
Primary Cohort 1:15 kg to ≤ 40 kg
Secondary  Cohort 2: > 40 kg to ≤[ADDRESS_87844] anned doses for Cohorts 1 and 2 are 100 mg and 200 mg, respectively .
Visit 1 : Screening
All patients arescreened to determine if they are eligible to participate in the study.
The study  and potenti al risks areexplained to the patient and their parent or guardian .
The informed consent form (ICF) and pati ent assent form  must be signed before any  study  
procedures are performed.
Screening will occur 28 day s to 3days prior to lasmiditan dosing.
Visit s 2–3: Dosing and PK Assessment s
Enrolled patients and patient’s parent or guardian will receive instructi ons regarding study  
procedures prior to dosing.
Day 1(Visit2)
Patients arrive at the Clinical Research Unit ( CRU )for assessments prior to dosing .
Patients receive the single lasmiditan dose .
Patientscan go home after the 12-h our assessments.   Patients may be off ered the 
opportunit y to spend the night depending on CRU capabilit ies.
Day 2(Visit 3)
Patient assessments are done at the CRU approximately 24 hour s after dosing .
Visit 4 /801
Visit 4/801 will  occur approximately  14 days after dosing .
Visit 801 –Patients in Japan and those who will not proceed to the 3 -month addendum will 
complete assessments according to Visit 801 in the Schedule of Activit ies.
Visit 4 –Patients conti nuing to the addendum will com plete assessments according to the 
Schedule of Act ivities in the addendum.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 19
LY5731444.2. Scientific Rationale for Study Design
This is an open -label, single -dose study  to determine the PK, safet y,and tolerabilit y of 
lasmiditan in pediatric migraine pat ients.  This study  is part of a pediatric migraine clinical 
development program ,and the data from  this study will be used to inform dose selection in 
subsequent clinical studies intended to provide pi[INVESTIGATOR_80485] y data to support use of 
lasmiditan for acute treatment of migraine in children and adolescents.
The single -dose administration:
limits exposure of patients to lasmiditan, compared with repeat dosing
is consistent with the intended use of lasmiditan as a medication that is taken on an “as 
needed” basis for abortive treatment of migraines
is appropriate to assess PK, safet y,and tol erabilit y of lasmidi tan.
Body Weight Selection
The lower end of the weight range for this study  is 15 kg ,as only 1% of pediatric subjects who 
are 6 y ears of age wei gh < 15 kg, based on US pediatric growth charts .  Addit ionally , in Japan, 
<3% of pediatric subjects who are 6 y ears of age wei gh < 15.6 kg (Kato et. al. 2014).
The higher end of the wei ght range for this study  is
55 kg. The body  weight eval uated in adul ts 
ranged from 48 to 115 kg, with limit ed exposure data in subjects ≤55 kg (l ower 5thpercentile).  
Therefore, the body  weight range of 15 to 55 kg is considered suitable for evaluat ion in this 
study .  For body  weights above 55 kg, the pediatric exposure of lasmiditan is anticipated to be 
similar to that of adults of the same body  weight for a given dose.
Pharmacokinetics
This study  is designed to characterize the PK of lasmiditan after a single dose of lasmiditan.  
Blood sam ples will be collected for 24 hours after dosing, which is considered adeq uate to 
characterize the PK profile in pediatric patients.  The plasma concentration of lasmiditan is an 
objective measurement ; therefore, the open -label design i s appropri ate for thi s evaluat ion.
Japanese Patients
Data from Japanese pediatric patients wil l be used to inform subsequent clinical studies in 
Japanese patients.
4.3. Justification for Dose
The pl anned doses for this study  are 100 m g for pati ents who are 15 to ≤40 kg and 200 mg for 
patients who are >40 to ≤[ADDRESS_87845] for the 200 -mg dose.  It is 
important to assess pediatric dose(s) predicted to achieve exposures comparable to adult 200-mg 
exposure, because demonstrating efficacy  in pediatri c migraine studi es has been challenging, in 
part because o fthe high pl acebo rates reported in these studies (Evers 2006; Fernandes 2008).
Although [ADDRESS_87846] lasmidi tan exposure s in pediatri c pati ents at 5 -kg body  weight increments 
(Figure LAHX. 1).
The m aximum  observed drug concentrati on(
Cmax)was considered the primary exposure 
measure used to guide dose select ion,as it is expected to be a more rel evant response for acute 
treatm ent.  For pediatric pat ients (15 to ≤40 kg) receiving 100 mg, the predicted ratio of mean 
Cmaxranged from 0.68 for 40 kg to 1.19 for 15 kg , relat ive to that of adul ts receiving 200 m g.  
For pedi atric pati ents ( >40 kg to ≤55 kg) receiving 200 mg, the predicted ratio of mean peak 
exposure C maxranged from 1.22 for 55 kg to 1.37 for 45 kg , relat ive to that of adults receiving 
200 m g.
Therefore, the proposed dosing regimen should provi de exposures in pediatric pat ients, 
comparable to the predicted range of adult 200-mg exposure s.  PK exposure data will be 
reviewed during the study .  The dose may be adjusted , if lasmiditan exposure issubstantially 
different fr om PK predicti ons.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 21
LY573144Abbreviations: AUC =area under the concentration -versus -time curve ; Cmax=
maximum observed drug concentration; PI = prediction interval.
The boxes depi[INVESTIGATOR_80486]; whiskers depi[INVESTIGATOR_21373] 90% 
prediction interval (PI) in pediatric subjects.  The black solid and dashed lines depi[INVESTIGATOR_80487] 90% PI [INVESTIGATOR_8178] [ADDRESS_87847] patient .

H8H-MC-LAHX Clinical Pharmacology Protocol Page 22
LY5731445.Study  Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
5.1. Inclusion Criteria
Study  investigator(s) will review patient history  and screening test resul ts at Visi t [ADDRESS_87848] .
A pat ientis eligible for inclusion in the study only if all the criteria apply at screening.
Type of Patient and Disease Characteristics
[1] Patient isbetween 6 and <18 y ears of age .
[2] have a history  of migraine with or wi thout aura, as defined by [CONTACT_80500], 3rdedition 
guidelines (ICHD -3 2018) migraine definit ions and meets the fo llowing cri teria:
history  of migraine attacks for more than 6 m onths
reports ≥
2and ≤15migraine attacks per month in the 2 months prior to screening
[3] are migraine free on day  of lasmiditan administration at the time o f predose 
assessments .
[4]have a minimum body  weight of 15kg and a maximum o f 55 kg .
[5]are able to swallow a tablet .
[6]have received age -appropri ate immunizations according to their country -specific 
public healt h policy as confirmed b y patient’s immunizat ion record .
Informed Consent and Patient Agreements
[
7] the patient and the patient’s pare nt or guardian must understand the nature of the 
study .  The pati ent’s parent or guardian must sign an ICF and the patient must 
sign an informed assent document as required by  [CONTACT_80501].
[
8] are reliable and willing to make themselves available for the durati on of  the study  
and are willing to follow study  procedures .
[
9] A gree not to post any  personal medical data related to the study  or information 
related to the study  on any  websi te or social  media si te, such as Facebook, 
Twitter, Snapchat, Instag ram, Google+, until notification that the study  has 
completed.
[
10] Are male or female
If female, m
ust agree to abi de by [CONTACT_80502] :
H8H-MC-LAHX Clinical Pharmacology Protocol Page 23
LY573144Adolescent females who have started menses (even 1 cycle and any  amount 
of spotting) are considered to be of childbearing potential.
Females of childbearing potential must agree to use a highly effect ive 
method of contraception (that is,one with less than 1% failure rate ) such as 
combinat ion oral  contraceptives , implanted/injected contraceptives , 
intrauterine de vices, or a sterile partner until [ADDRESS_87849] dose of 
study  medicat ion.
Females of childbearing potential who are abst inent (if this is co mplete 
abstinence, as their preferred and usual lifest yle) or in a same -sex 
relationship (as part of their preferred and usual lifest yle)must agree to 
either rem ain abst inent or stay in a same -sex rel ationship wit hout sexual 
relationships wit h males.
Periodic abst inence (for example, calendar, ovulation, symptothermal, 
post-ovulation methods), decl aration of  abstinence just for the duration of a 
trial, and wi thdrawal are not acceptable methods of contraception.
Females not of childbearing potential may part icipate and include those
who are infertile because of surgical sterilization by  [CONTACT_31658] , bilateral  
oophorectomy , or tubal  ligation,or who have a congenital ano maly such as 
mullerian agenesis .
5.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at 
screening and/or enrollment:
Medical Conditions
[
11] Have a history  or clinical evidence o f congenital heart disease ,suspected or
confirmed; or a hi story  of stroke .
[12] H ave electrocardi ogram  (ECG )showing abnormalit ies co mpat ible with acute 
cardi ovascular events and/or serious cardiovascular disease ri sk.
[13] H ave had my ocardial  infarcti on,unstable angina, percutaneous coronary  
intervent ion, or coronary artery by[CONTACT_80503] 6 m onths of screening
.
[14] H ave planned cardio vascular surgery or percutaneous coronary  angioplast y .
[15] H ave liver tests outside the normal range that are clinically  significant
alanine aminotransferase (ALT) >2x upper limit of normal (ULN), or 
total bilirubin level (TBL) >1.5x ULN, or 
alkaline phosphatase (ALP) >2x ULN. 
Except ions
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87850] results outside the norm alrange arediscussed and judged not 
clinically significant by  [CONTACT_32837] ( Lilly )Medical
oPatients wi th TBL ≥1.5x ULN andthe following criteria for Gilbert 
syndro me:
Bilirubin is predo minantly indirect (unconjugated) at screening 
(directbilirubin wit hin normal limits)
Absence of liver disease
ALT, aspartate aminotransferase (AST), and ALP ≤1x ULN at 
screening
Hem oglobin not si gnificant ly decreased at screening
.
[16] H ave, in the judgment of the invest igator, apsychiatri c disorder as defined by 
[CONTACT_80504] c and Stati stical Manual  of Mental  Disorders, 5thEditionthat 
woul d interfere wi th adherence to study  requi rements or safe part icipation in the 
trial.
[
17]Are, in the j udgment of the invest igator , actively suicidal and therefore deemed 
to be at significant risk for suicide .
[18] At baseline:
have answered “yes” to either Quest ion 4 or Questio n 5 on the “Suicidal 
Ideati on” porti on of  theColumbia -Suicide Severi ty Rating Scale ( C-SSRS ), or 
have answer ed“yes” to any  ofthe suicide -related behaviors on the “suicidal 
behavior” portion of the C-SSRS ,and the ideat ion or behavior occurred within 
the past m onth.
[19] A re pregnant or nursing.
[
20] Have , in the j udgment of the invest igator, an acute, serious ,or unstable medical 
condi tion, or a hi story  or presence of any  other medi cal illness that woul d 
precl ude study  parti cipat ion
.
Prior and Concomitant Therapy /Substances of Abuse
[21] H ave used opi [INVESTIGATOR_80488] -containing analgesic s>3x per mont h for the 
treatm entof pain in more than [ADDRESS_87851] 6 months (opio idadministrati on in 
an emergency setting [either urgent or emergent] may be an except ion.).
[22]Have a history  of drug or al coho l abuse/dependence within 1 year prior to Visit 
1
(excessive or compulsive use as judged by [CONTACT_093]), or are currently 
using drugs of abuse (including opi[INVESTIGATOR_2438], barbiturates, and marijuana), or any
prescribed or over- the-counter medicat ion in a manner that the invest igator
considers indicat ive o f abuse/dependence.
[23] Have a posi tive urine drug screen for an y substances of abuse .One retest is 
allowed if the urine drug screen is posit
ive, at the investigator ’s discret ion.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 25
LY573144[24]Are ona CNS active drug, which is known to affect levels of attenti onor 
sedat ion, such as a benzodiazepi[INVESTIGATOR_80489] y, or stimulants for 
Attention Deficit Hyperact ivity Disorder.
[25] H ave known allergi es to l asmidi tan, rel ated com pounds ,or any  com ponents of 
the form ulation.
Diagnostics Assessments
[26] H avea history  of any t ype of headache except for migraine with or without aura, 
tension ty pe headache or m edicat ion overuse heada
che, as defined by [CONTACT_25420] 3. 
Migraine subtypes including sporadic or familial hemiplegic migraine and 
migraine with brainstem aura, previously known as basilar t ype migraine, should 
be excluded.
[27] Have a history  of traum atic head injury associated with significant change in the
qualit y or frequency of their headaches, including a new onset of migraine
following traum atic head injury or a history  of post -traumat icheadache .
[
28] Have a known history  of intracranial tum ors or developmental malformat ions 
including Chiari malformat ions.
Prior/C oncurrent Clinical Trial Experience
[
29] A re current lyenrolled in a clinical  study  involving an investigational product or 
any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study.
[
30] H ave participated , within the last [ADDRESS_87852] passed .
[31] H ave previ ously com pleted or withdrawn from this study  or any  other study  
investigat ing lasmiditan , and have previously  
received the invest igational 
product .
Other Exclusions
[32]Are legally incapacitated.
[
33] Are children of invest igator site personnel direct ly affiliated with this study  
and/or their immediate families.  Immediate family is defined as a spouse, 
biological  or guardi an, child, or sibling.
[34] A re children of Lilly emplo yees .
[35]Have donated m ore than a single unit of blood within 4 weeks prior to screening 
or intend to do nate blood during the course of the study.
[
36]In the opi[INVESTIGATOR_1649] o f the invest igator or sponsor, are unsuitable for inclusio n in the 
study .
H8H-MC-LAHX Clinical Pharmacology Protocol Page 26
LY5731445.2.1. Rationale for Exclusion of Certain Study Candidates
Criteria [11] through [ 20] exclude medical condit i ons, [21] through [2 8] exclude conco mitant 
medicat ion, substances of abuse ,and m edical history  that may confound the assessment of study  
endpo ints, 
[29] through [ 3 1] exclude concurrent clinical trial experience, and [33] and [3 4] 
prevent conflict of interest in stu dy parti cipants.
5.3. Lifestyle and/or Dietary Considerations
Throughout the study , patients may undergo medical assessments and review o f compliance wi th 
requi rements before continuing in the study .
5.3.1. Meals and Dietary Restrictions
Patients will:
fast overnight prior to the day  of dosing with the except ion of a light breakfast, such as
cereal  with fat-free milk or toast or whi te rice,2 hours prior to the time of dosing
abstain from water 1 hour before and after dosing, except for up to 240 mL of water 
given with the dose
fast until approximately  2hours after dosing, at which time a meal will be served.
5.3.2. Caffeine , Alcohol ,and Tobacco
From  approximately  48 hours pri or to dosing , and up to 24 hours after dosing, pati ents are not 
allowed to :
consume xanthine -or caf feine-containing food and drink
Example s -cola, chocol ate drinks, tea, coffee, and energy drinks containing 
methylxanthine (caffeine, theophylline, or theobromine)
consume alcoho lic beverages
use tobacco products .
Limit s may be adj usted to m eet local requi rements if l ocal requirements are m ore stringent.
5.4. Screen Failures
At Visit 2, inclusio nand exclusio n criteria will  be reviewed prior to the first dose of 
investigat ional product .
Screen failures are defined as p atients who consent to participate in the study  but do not meet the 
enrollment criteria and do not receive any  dose of investigational product .
Based on the clinical judgment of the invest igator, patients who fail to qualify at enrollment may 
be rescreened at a later date.  Only [ADDRESS_87853] be repeated. However, if the rescreen visit is within 30 days fro m the original screening 
visit and it was a result of only specific out -of-range value/fi ndings, then only those assessments 
shoul d be repeated and not the ent ire laboratory panel.
A minimal set of screen failure informat ion is required to ensure transparent reporting o f screen 
failure participants to meet the Consolidated Standards of Reporti ng Trials (CONSORT) 
publishing requirements and to respond to queries fro m regulatory  authori ties.  Minimal 
inform ation includes demography, screen failure details, eligibilit y criteria,and any  SAE .
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87854] ered
Lasmiditan 50 -mg and 10 0-mgtabletswill be used in this study , to achieve a single total dose of 
either 100 mg or 200 mg (Table LAHX. 3).  The investigator will decide which tablet strength to 
administer to achieve the appropriate dose based on the patient’s abilit y to swall ow and pati ent’s 
preference.
Lasmidi tan will be administered orally , onDay 1,in a sitting posit ion.  
The actual time of the 
dose administered will be rec orded in the patient’s case report form (CRF).
Patients shoul d not lie supi[INVESTIGATOR_2525] 2hours after dosing, unless clinically indicated or for study  
procedures.
Table LAHX.3. Planned Treatment Regimen
Cohort 1 2
PatientBody Weight 15 kg to ≤ 40 kg >40 kg to ≤ 55 kg
Treatment Name [CONTACT_80524] (s)/
Dosage Level(s)[ADDRESS_87855] igator or designee is responsible for:
explaining the correct use of the investigational product (s) to the site personnel
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and collect ion
and returning all unused medicat ion to Lilly or its designee at the end of the study
6.1.1. Packaging and Labeling
Lasmiditan will be supplied to the clinics with bulk bottles of [ADDRESS_87856] will be labeled according to the country ’s regul atory  requi rements.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 29
LY5731446.2. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm all investigat ional product was received in good 
condition, and any discrepancies are reported and resolved before use of the study  drug.
Only pat ients enrolled in the study  may receive investigational product or study  materials, and 
only authori zed si te staff may supply  or administer invest igational product .  All invest igational 
product shoul dbe stored in a secure, environmentally  controlled and m onitored (m anual  or 
autom ated) area in accordance wit h the labeled storage condi tions wi th access limited to the 
investigator and authorized site staff.
Theinvest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance ( such as
recei pt, reconciliat ion,and final disposit ion records) .
6.3. Measures to Mi nimize Bias: Randomization and Blinding
This is an open -label study . Patients who meet all criteria for enrollment at Visit [ADDRESS_87857] 3 m onths pri or to Visit 1 .
This study  will be conducted during a migraine -free peri od; therefore concomitant acute 
medicat ions for migraine or migraine symptoms on the day of Visit [ADDRESS_87858] igator, 
according to label reco mmendat ions.
A topi[INVESTIGATOR_80490]/needle insertion .
If the need for concomitant medicat ion other than acetaminophen or topi[INVESTIGATOR_80491], 
inclusio n or continuat ion of the pati ent may be at the discret ion of the investi gator af ter 
consultation wit h Lilly medical. All conco mitant medicat ions, whether prescript ion or over the 
counter, used at baseline and/or during the course of the study , must be recorded on the 
appropriate Conco mitant Medicat ionCRF.
6.6. Dose Modification
The pl anne d dose i s 100 m g and 200 m g in pediatric pat ients with body  weight ≥15 kg 
to ≤40kg 
and >40 kg to ≤[ADDRESS_87859] 3 patients with evaluable PK data in 
the primary  cohort (Section 9.4.3 ).
6.7. Treatment after theEnd of the Study
This sect ion is not applicable to this study .
H8H-MC-LAHX Clinical Pharmacology Protocol Page 31
LY5731447.Discontinuation of Study  Treatment and Participant 
Discontinuation and Withdrawal
7.1. Discontinuation from Study Treatment
This is a single -dose study .  If a patient discont inues afterreceiving the single dose of lasmiditan, 
early  discont inuat ionprocedures will be co mpleted per the Schedule of Activit iesof this 
protocol .
7.2. Participant Discontinuation and Withdrawal from the Study
Patients will be discont inued in the fo llowing ci rcumsta nces:
Enrollment in any other clinical study  involving an invest igational product or enrollment 
in any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study.
Parti cipation in the study  needs to be stopped fo r medical, safet y, regul atory , or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP) .
Invest igator Decisio n
othe invest igator decides that the patientshould be discontinued from the study .
oif the patient, for any  reason, requi res treatm ent with another therapeutic agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent .
PatientDecision
othe patientrequests to be wi thdrawn from  the study , or
othe parent or patient’s guardian requests that the patient be withdrawn fro m the 
study .
Parti cipants discont inuing from the study  prem aturely for any  reason shoul d com plete AEand 
other safet y follow-up per Section 1.3(Schedule of Act ivities), Section 8.3(Adverse Events 
and Serious Adverse Events), and Section 8.2(Safety Assessments) of this protocol.
7.2.1. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ifies a patient who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discussio n must occur between Lilly Medical and the invest igator to 
determine if the pat ient may  cont inue in the study .  If both agree i t is medically  appropriate to 
continue, the invest igator must obtain documented approval fro m Lilly Medical to all ow the 
inadvertent ly enro lled pat ient to conti nue in the study with or without treatment with 
investigat ional product.
Safety follow-up is as outlined in Sect ion 1.3(Schedule of Act ivities), Section 8.3(Adverse 
Events and Serious Adverse Events), and Section 8.2(Safet y Assessments) of thisprotocol .
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87860] patient s who fail to return for a schedule d visit or were otherwise 
unable to be fo llowed up by  [CONTACT_4179].
H8H-MC-LAHX Clinical Pharmacology Protocol Page 33
LY5731448.Study Assessments and Procedures
The Schedule o f Activitiesdetail sthe study  procedures and their timing (including tolerance 
limits for timing).
Appendix [ADDRESS_87861] or Clinical Research Physician (CRP )/scientist will mo nitor 
safet y data throughout the course of the study .
8.2.1. Physical Examination
For each patient, a complete physical examinat ion (excluding pelvic and rectal examinat ions) 
will be performed according to the Schedule o f Activit ies.  A com plete physical examinat ion 
may be repeated at the investigator’s discret ion at any time a pat ient presents with physical 
complaints.  A com plete physical examinat ion will incl ude, at a minimum, assessments of the 
cardi ovascular, respi [INVESTIGATOR_696] , gastrointestinal ,and neurol ogical  systems.
8.2.2. Vital Signs
For each patient , vital sign m easurements shoul d be conducted according to the Schedule of 
Activities.
Vital signs will  consist of 1 pulse rate , 1 temperature, and 3 blood pressure ( BP)measurements . 
Three consecut ive BP readings will be recorded at intervals of at least [ADDRESS_87862] triplicate vital sign can be used as the supi[INVESTIGATOR_050]/semi -recumbent vi tal sign for 
the calculat ion of orthostatic changes.
Blood pressure and pulse rate measurements :
will be taken when the patient is in a s upi[INVESTIGATOR_2547]
shoul d be preceded by [CONTACT_2669] [ADDRESS_87863] for the pat ientin a quiet setting wit hout 
distracti ons (for example, televisio n, cell phones)
will be co llected using the appropriate size pediatric BP cuffs
will be assessed wit h a completely automated device
oManual techniques will be used only if an automated device is not available.
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87864] 2 mi nutes. If the patient feels unable to stand, supi[INVESTIGATOR_80492]. Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of 
dizziness or posture -induced symptoms.  Addit ional vital signs m ay be measured du ring each 
study  period if warranted.
Any clinically  significant findings from vital sign measurement sthat resul t in a diagnosi s shoul d 
be reported to Lilly or its designee as an AE via electroni c case report form ( eCRF ).
Any abnormal finding for vital sig ns at [ADDRESS_87865] ion.
Electrocardiograms will be interpreted by  a qualified physician ( the investigator or qualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
patient is st ill present for immediate patient managem ent, shoul d any clinically  relevant findings 
be ident ified.
Digital ECGs will be electronically transmitted to a central ECG laboratory  designated by  [CONTACT_11007] .  
At a future time, the stored ECG data may be overread at the central ECG laboratory for furthe r 
evaluat ion of machine -read m easurements or to meet regulatory  requi rements.
Any clinically  significant findings from ECGs that result in a diagnosis should be reported to 
Lilly or i ts desi gnee as an AE via eCRF.
Any abnormal finding for ECG s at [ADDRESS_87866] ivities.  Use of local anesthetics (for example, EMLA cream) consistent with 
local prescribing informat ion is permitted during the study  visit to ease di scomfort associated 
with veni punctures.
Lilly or i ts desi gnee will  provide the investi gator wi th the resul ts of laboratory  tests analyzed by  
a central  vendor , if a central vendor is used for the clinical trial .
Alkaline phosphatase laboratory resul ts may  be out of the norm al range in pediatri c patients 
because of normal bone growth processes, and co llection of a blood sample for bone ALP may 
be requested by  [CONTACT_3174] a reflex test if the ALP resul t is high.
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87867] document their review of each laborat ory safety  report.
[IP_ADDRESS]. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3xULN, ALP ≥ 2xULN , or elevated TBL ≥2x
ULN, liver tests ( Appendix 3 ) shoul d be repeated wi thin [ADDRESS_87868] bilirubin, gamma -glutamyl transferase (GGT), and creatine kinase to confirm the 
abnorm ality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
worsens, clinical and laboratory  monitoring shoul d be ini tiated by  [CONTACT_80505] h the CRP/CRS .  
Moni toring should conti nue unt il levels norm alize and/or are 
returning t o approximate baseline levels.
Addit ional safet y data should be co llected if 1 or more of the following condit ions occur:
elevation of serum  ALT to ≥5xULN on 2or more consecut ive blood tests
elevated serum  TBL to ≥
2xULN (except for cases of known Gilber t’s syndrome)
elevation of serum  ALP to ≥
2xULN on 2 or more consecut ive blood tests
patient discont inued fro m treatm ent because of a hepati c event or abnormalit y of 
liver tests
hepat ic event considered to be a nSAE.
8.2.5. Suicidal Ideation and Behavior Risk Mon itoring
[IP_ADDRESS]. C-SSRS
Columbia -Suicide Severit y Rating Scale (C -SSRS) is ascale that captures the occurrence, 
severit y,and frequency  of suicidal ideation and behavior during the assessment period via a 
questionnaire .  The scale was devel oped by  [CONTACT_80506] h (NIMH) trial 
group (TASA) for the purpose of being counterpart to the Columbia Classificat ion Algorithm o f 
Suicide Assessment (C -CASA) categori zation of  suicidal events .
Suicidali ty will be assessed by  [CONTACT_80507]’s version of t he C-SSRS (Posner et al. 2011).  The 
C-SSRS scale includes suggested questions to solicit information needed to determine if a 
suicide-related though t or behavior occurred during the assessment period.
The Self -Harm  Supplement should be completed every  time the patient is assessed by  C-SSRS .  
Ifthere are posi tive findings on the Self -Harm  Suppl ement , then the Lilly Self -Harm  Follow-Up 
form will be used to collect addit ional information to allow for a more complete assessment of 
these behaviors .
The C -SSRS and a corresponding Self -Harm  Supplement Form  will be used for assessment of 
the pati ent according to the Schedule of Act ivities by [CONTACT_80508].
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87869] ing condit ion(s) and the occurrence and nature of any  AEs.
Nonserious AEs obtained through the questionnaire are recorded and analyzed separately .
Only SAEsand AEs l eading to discontinuation elicited through the C -SSRS are to be recorded as 
AEs via the CRF.  Serious adverse events must be reported to Lilly or its designee within 24 
hours as SAEs.
[IP_ADDRESS]. Columbia- Suicide Severity Rating Scale –Child Version
The C -SSRS captures the occurrence, severit y, and f requency of suicidal ideat ion and/or 
behavior during the assessment period.  A children’s versio n of the C -SSRS will be completed 
for all patients.  The scale includes suggested questio ns to solicit the ty pe of  inform ation needed 
to determine if suicidal ideat ion and/or behavior occurred.  Th e C-SSRS i s administered by 
[CONTACT_1746].  The tool was developed by  [CONTACT_80509] h trial 
group for the purpose of being a counterpart to the Columbia Classificat ion Algori thm of Suicide 
Assessment categorizat ion of sui cidal  events.  F or thi s study , the scale has been adapted (with 
permission fro m the scale authors) to include only  the porti on of  the scale that captures the 
occurrence of the [ADDRESS_87870] ion, sites shoul d not change the AE form.  If an event is serious or leads to 
discontinuat ion,this is an except ion where the SAE and/or AE leading to discont inuat ion should 
be included on the AE form and the process for reporting SAEs should be fo llowed.
[IP_ADDRESS]. Self-Harm and Follow -up Supplement Forms
The Self -Harm  Supplement Form is an administrative form to denote the presence of any  
reported self-harm events and is used to trigger a Self-Harm  Follow -Up form in the data capture 
system .  The Self-Harm Follow-Up form is a series of quest ions that provides a more detailed 
descript ion of the behavior.
As part of the C- SSRS, the Self -Harm  Follow -Up form  willbe co mpleted for each event if the 
patient reports 1or more self -harm events.
8.2.6. Cognition
Cogni tion will be assessed by [CONTACT_80510]  (2018 Cogstate Ltd).  This 
is a bri ef 15-to [ADDRESS_87871] well -established reliabilit y and validi ty 
for the repeated assessment of cognit ive function in children (Mo llica et al.2005).  Evi dence 
supports i ts use in children with chronic pain (Bred lau et al. 2015) and in other indicat ions such 
as mild traumat ic brain injury , schizophrenia, and acqui red immunodeficiency syndrome –
dementia co mplex (Maruff et al. 2009).
H8H-MC-LAHX Clinical Pharmacology Protocol Page 37
LY5731448.2.7. Height and Weight
Height and wei ght will  be assessed according to th e Schedule of Ac tivities.
Height will be measured using a stadio meter and measured in triplicate.
Weight m ust be measured once, and recorded to [ADDRESS_87872] wit hout rounding.
Instrum ents used for measuring height and weight should be appropriately and regularly  
calibrated.
All measurements of height and weight should be taken without shoes and after the 
removal of any heavy personal items (that is, large jewelry, wallets, coats, etc.).
8.2.8. Puberty and Menstrual Status
Pubertal  status, including menstrual history , will be determined by [CONTACT_80511]’s guardian, and results of 
blood hormone levels.   
8.2.9. Targeted Neurological Exam ination
A targeted neurological examinat ion will be performed at the visits and times specified in the 
Schedule of Act ivities.
Exam ination Components Considerations
General Speech Monitor for dysarthria or other speech changes 
during neuro logical examination and interactions
Motor Upper and lower extremity 
strength
ToneAssess for motor weakness
Assess for decrease or increase in tone
Cerebellar Arms extended
Finger –nose–finger
Heel to shin (supi[INVESTIGATOR_050])
Rapid alternating movement 
(pronation/supi[INVESTIGATOR_80493])Assess for tremor and coordination ;
ataxia of lower extremities ; 
dysdiadochokinesia
Gait Casual
Toe
Heel
TandemAssess for strength and coordination
Reflexes Biceps
Brachioradialis
Patellar 
Ankle jerkAssess for upper and lower limb reflexes
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87873] , via CRF ,the 
occurrence and nature of each patient’s preexist ing conditions, including clinically significant 
signs and symptoms of the disease under treatment in the study .  Addit ionally , site personnel will  
record any  change in the condit ion(s) and the occ urrence and nature of any  AEs.
The invest igator will interpret and document whether or not anAE has a reasonab lepossib ility 
of being related to study treatment or a study  procedure, taking into account the disease, 
concomitant treatment ,or pathol ogies.
A “reasonable possibilit y”means that there is a potenti al cause- and-effect rel ationship between 
the invest igational product, study  device ,and/or study  procedure and the AE .
Planned surgeries should not be reported as AEs unless the underlying medical condi tion has 
worsened during the course of the study .
8.3.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in 1 of the f ollowing:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience (that is, immediate risk o f dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospi[INVESTIGATOR_313] m ay jeopardi zethe patientor may require intervent ion to prevent 
one of the other outcomes listed in the definit ion above.
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87874], the SAE should be reported to the sponsor according to 
SAE reporting requirements and t imelines (see Section 8.3.3 ) if it is considered reasonably 
possibly  related to study  procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within [ADDRESS_87875] addit ional data collected using 
the CRF.
Pregnancy (during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements ,any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in subjects once they hav e 
discontinued and/or completed the study  (the partici pant di sposi tion CRF has been com pleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study , and he or she considers the event reasonably  possibly  related to 
the study  treatm ent or study  parti cipati on, the investi gator m ust prom ptly notify Lilly.
8.3.2. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
[LOCATION_002] [ADDRESS_87876] ive 2001/20/EC and the 
associ ated detailed guidances or nati onal regulatory  requirements in parti cipat ing countries 
requi re the reporting of S[LOCATION_003]Rs .  Lilly  has procedures that will be followed for the 
ident ificat ion,recording ,and expedited reporti ng of S[LOCATION_003]Rs that are consistent with global 
regul ations and the associated detailed guidances.
8.3.3. Time Period and Frequency for Collecting AE and SAE 
Information
All AEs and SAEs will be collected from the signing of the ICF until the follow-up visit at the 
time points specified in the S chedule of Activities(Secti on 1.3).
Medical occurrences that begin before the start of study  interventi on but after obtaining informed 
consent will be recorded on the Medical History /Current Medical Condit ions sect ion of the CRF 
and not on the AE sect ion.
All SAEs will be recorded and report ed to the s ponsor or designee immediately , and under no 
circumstance shoul d this exceed [ADDRESS_87877] igator learns of any SAE, including a death, at any t ime after 
a pat ienthas been discharged from the study , and he/she considers the event to be reasonably 
related to the stu dy intervent ion or study  parti cipati on, the invest igator must prompt ly notify  the 
sponsor .
8.3.4. Method of Detecting AEs and SAEs
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open -ended and 
nonleading verbal questioning of the participant i s the preferred method to inquire about AE 
occurrences.
8.3.5. Follow -Up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow up each pati ent 
at subsequent visits/contacts. All SAEs, and nonseri ous AEs of special interest ( Section 8.3.8 ),
will be fo llowed up until reso lution, stabilizat ion, the event is otherwise explained, or the pati ent 
is lost to fo llow-up as defined in Sect ion7.3.
8.3.6. Regulatory Reporting Requirements for SAEs
Prom pt notificat ion by [CONTACT_80512] a nSAE to the sponsor is essent ial so that l egal 
obligat ions and ethical responsibilit ies toward the safet y of parti cipants and the safet y of 
a study  intervent ion under clinical invest igation are m et.
The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply wi th country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authorit y, Institutional Review Boards 
(IRB s)/Independent Ethics Committees (IEC s), and invest igators.
Invest igatorsafet y reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requi rements and sponsor policy and forwarded to investigators as necessary .
An invest igator who receives an invest igator safety report describing a nSAE or other 
specific safet y informat ion (for example , summary or list ing of SAEs) fro m the sponsor 
will review and then file it along wit h the IBand will notify the IRB/IEC, if appropriate 
according to local requirements.
8.3.7. Pregnancy
Details o f all pregnancies in female participants and, if indicated, female partners of male 
participants will be co llected after the start of lasmiditan dosing and unt il at least 1month 
following the last dose of lasmiditan .
To fulfill regulatory  requi rements ,any pregnancy should be reported fo llowing the SAE process 
to collect data on the outcome for both mother and fetus.
Abnorm al pregnancy outcom es, such as the following, are also considered SAEs:
spontaneous abortion
H8H-MC-LAHX Clinical Pharmacology Protocol Page 41
LY573144fetal death
stillbirth
congenital anomalies
ectopi c pregnancy.
8.3.8. Safety Topi[INVESTIGATOR_80494], the following safet y topi[INVESTIGATOR_80495]:
Cardi ovascular safety
Hepati c safety
Neurol ogic effects, including injuries and accidents secondary  toneurologic AEs 
Road traffic accidents
Abuse potential .
8.3.9. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies to ensure the safet y of study  participants, monitor qualit y, and to facilitate 
process and product improvements.
Parti cipants will be instructed to contact [CONTACT_17074] a 
complaint or probl em wi th the invest igational product so that the situation can be assessed.
8.4. Treatment of Overd ose
This is a single -dose study .  This sect ion is not applicable for this study .
8.5. Pharmacokinetic s
At the visit s and t imes specified in the Schedule of Act ivities, venous blood samples o f a 
maximum o f 2mL each will be co llected to determine the plasma conc entrati ons of  lasmidi tan. 
An indwelling catheter is recommended for blood collect ion on Day  1.  Patients who choose to 
go home after the [ADDRESS_87878] ion and 
handling of blood samples will be provided by  [CONTACT_456] .  The actual date and time (24 -hour 
clock time) of each sampling will be recorded.
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87879] 11 patient s with evaluable PK data
for the primary cohort (body  weight between 15 kgand 40 kg, inclusive) .  Patients who do not 
have evaluable PK data may be replaced.
From  the popPKanalysis in adults , the interpatient coefficient of varia tion(CV) was estimated to 
be 43% for C maxand 39 % for AUC.  Assuming the CV of total variabilit y is not l arger than 45% , 
[ADDRESS_87880] 80% coverage probabilit y that the 95% confidence 
intervals (CIs)for the geometric mean of these key PK parameters will be wit hin 70% and 140%.  
The CV for apparent total body  clearance and apparent central vo lume of distribut ion are similar
to those of C maxand AUC and, therefore, the precision of estimates for these parameters are 
expected to be sufficient (Wang et al . 2012 ).
Cohort [ADDRESS_87881] 6 patients with evaluable PK data for 
the secondary  cohort (body  weight >40 kg and ≤55 kg) .This sample size is custom ary for Phase 
[ADDRESS_87882] icsmay be sum marized by  [CONTACT_11338] (Japanese vs . non- Japanese ), if appropri ate.
9.4. Statistical Anal yses
Statistical analysis o f this study  will be the responsibilit y of Lilly or i ts desi gnee .
Pharmacokinet icanalyses will be conducted on data fro m all patientswho receiv e adose of the 
investigat ional product and have evaluable PK data.
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87883] , whether or not they  com pleted all  protocol  requi rements.
Data analys es willbe pr esented by  [CONTACT_80513] , age, body  surface area, and glo merular 
filtrat ion rate.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.
9.4.1. Safety Analyses
Safety analyses will be conducted based on safet y data obtained fr om the screening , PK/safet y 
assessment, and follow-up/early  discontinuat ionphases of the study .
[IP_ADDRESS]. Clinical Evaluation of Safety
All invest igational product and protocol procedure -
related AEs will be listed, and if the 
frequency  of events all ows, safet y data will be summarized using descriptive methodology .
Adverse event s will be classified by  [CONTACT_941] m ost sui table term  from the most current Medical 
Dictionary for Regulatory  Activities (MedDRA ) versi on.
Theincidence of TE AEs will be presented by [CONTACT_80514].  AEs reported to occur prior to enrollment will be 
distinguished from those reported as new or increased in se verity during the study .
All SAEs will be reported and classified by  [CONTACT_941] m ost suitable term  from the most current 
MedDRA versio n.
[IP_ADDRESS]. Statistical Evaluation of Safety
Safety param eters for analysis will be :
AEs (including clinically  significant ECGs)
clinical laboratory parameters
vital signs
C-SSRS assessments
Cogstate Pediatric Brief Battery parameters .
The parameters will be listed, and summarized using standard descriptive statist ics.  Addit ional 
analysis will be performed if warranted upon review of the data.
Safety param eters m ay be summarized by [CONTACT_11338](Japanese vs . non- Japanese ), if appropri ate.
9.4.2. Pharmacokinetic Analyses
[IP_ADDRESS]. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for lasmiditan will be calculated by  [CONTACT_80515], and listed and 
summarized using descript ive statist ics.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 45
LY573144The primary  parameters for analysis will be Cmax, tmax, and AUC of lasmiditan .
Other noncompartmental parameters, such as half -life, appare nt clearance, and apparent volume 
of distribut ion may be reported.
In addit ion to estimates of geo metric means, the corresponding 95% CIswill also be determined .
Pharmacokinet ic param eters m ay be summarized by  [CONTACT_11338](Japanese vs . non- Japanese )if 
appropriate.
Addit ional analysis will be performed if warranted upon review of the data.
9.4.3. Data Review during the Study
Safety and PK data will be reviewed on an ongo ing basis.  Doses may be adjusted when data are 
available fromat least 3 patients with evaluable PK data in the primary cohort.  The purpose of 
the review is to assess safet y/tolerabili ty,evaluate PK data ,and inform the dosing of subsequent 
patients.  The invest igator and the Lilly sponsor team will make the determinat ion regarding 
dosing ,based on their review of the safet y and PK data.  If lasmiditan plasma concentrations are 
unexpected relat ive to PK predict ions, then the dose may  be adjusted.  Addit ional reviews may 
be perform ed, as deemed appropriate .
9.5. Interim Analyses
Because all patients in a cohort receive the same treatment, review of nonfinal data is not 
considered an interim analysis.  Therefore, there will be no interim analyses in this study .
9.6. Data Monitoring Committee
An external data m onitoring committee (DMC) will be used for this study .The DMC will 
review safet y data on an ongoing basis concurrent with team and invest igator reviews.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 46
LY57314410. Supporting Documentation and Operational 
Considerations
10.1. Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Cons iderations
This study  will be conducted in accordance wit h the protocol and with:
1.consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Science s (CIOMS) I nternat ional Ethi cal Guidelines
2.applicable Internati onal Council for Harmonisat ion (ICH) GCP Guidelines
3.applicable laws and regulations .
Some of the obligat ions of the sponsor will be assigned to a third party  organizat ion.
Ethical Review
The invest igator or appropriate local representative must give assurance that the ethical review 
board (ERB) was properly const ituted and convened as required by [CONTACT_80516].
Docum entati on of  ERB approval  of the protocol, the ICF ,and Assent Form must be provided to 
Lilly before the study  may begin at the invest igative sites.  Lilly or its representatives must 
approve the ICF before it is used at the invest igative sites.  All ICFs must be compliant with the 
ICH gu ideline on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF and Assent Form
relevant curri cula vi tae.
10.1.2. Informed Consent
The invest igator is responsible for:
ensuring that the patient or patient’s legal representative understands the nature of the 
study , the potenti al risks and benefi ts of participating in the study , and that thei r 
participat ion is voluntary.
ensuring that informed consent is given by [CONTACT_80517].  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
perform ance of any protocol  procedures and prior to the administration of invest igational 
product.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 47
LY573144answering any quest ions the pati ent or pati ent’s legal repre sentative may have 
throughout the study  and sharing in a timely manner any  new informat ion that m ay be 
relevant to the pati ent’s willingness to continue his or her participat ion in the study.
provi ding a copy  of the ICF to the participant or the participan t’s legal representative and 
retaining a copy  on file.
A legal representative must give informed consent for a child to participate in this study.  In 
addition to inform ed consent given by [CONTACT_80518], the child may  be requi red to give 
docum ented assent, if capable.
10.1.3. Data Protection
Parti cipants will be assigned a unique ident ifier by [CONTACT_093] . Any part icipant 
records or datasets that are transferred to the sponsor will contain the identifier only; 
participant names or any  information thatwould make the participant ident ifiable will 
not be transferred.
The parti cipant must be inform ed that hi s/her personal  study -related data will  be used 
by [CONTACT_17079] h local data protecti on law. The level o f disclosure 
must al so be e xplained to the participant.
The parti cipant must be inform ed that hi s/her m edical  records m ay be examined by 
[CONTACT_17080] y Assurance auditors or other authorized personnel appo inted by  [CONTACT_103], appropriate IRB/IEC members, and inspectors from regul atory  authori ties.
10.1.4. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .
After reading t he protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
10.1.5. Final Report Signature
[CONTACT_80525] f or this 
study , indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
If this invest igator is unable to fulfill this funct ion, another invest igator will be chosen by [CONTACT_80519].
The sponsor’s responsible medical o fficer and statistician will sign/approve the final clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately desc ribes the conduct and results of the study .
10.1.6. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
H8H-MC-LAHX Clinical Pharmacology Protocol Page 48
LY573144provi de instructi onal materi al to the study  sites, as appropriate
provi de sponsor start- up training to instruct the investigators and study 
coordinators.  This training will give instruction on the protocol, the complet ion 
of the CRFs, and study  procedures.
make periodic visit s to the study  site
be available for consultation and stay  in conta ct with the study  site personnel by  
[CONTACT_2319], tel ephone, or fax
review and verify  data reported to detect potential errors.
In addit ion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_80520].  Invest igators will be given notice before an 
audit occurs.
The invest igator will keep records of all original source data.  T his might include laboratory  
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original source 
docum ents.
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor.
An electronic data capture (EDC) system  will be used in this study  for the collect ion of CRF 
data.  The investigator maintains a separate source for the data entered by  [CONTACT_32864] -provided EDC system.  The invest igator is responsible for the 
ident ificat ion of any data to be considered source and for the confirmat ion that data reported a re 
accurate and complete by  [CONTACT_11003] .
Addit ionally , electroni c Clinical Outcome Assessment (eCOA) data, such as the cogni tion 
assessment ,will be di rectly recorded by [CONTACT_80521] a com puter.  The eCOA data will serve 
as the source documentation and the invest igator does not maintain a separate, written ,or 
electroni c record of these data.
Data collected via the sponsor- provided data capture system (s) will be stored at third parti es.  
The invest igator will have cont inuous access to the data durin g the study  and unt il 
decommissio ning of the data capture sy stem (s).  Prior to decommissio ning, the invest igator will 
receive an archival copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored e lectronically in 
the central  vendor’s database system and reports will be provided to the investigator for review 
and retention.  Data will subsequent ly be transferred fro m the central  vendor to the Lilly  data 
warehouse.
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87884] control s and requi rements in accordance wit h local 
data protecti on law.
The purpose and use of patient persona l information co llected will be provided in a written 
docum ent to the pati ent by  [CONTACT_456] .
10.1.7. Study and Site Closure
[IP_ADDRESS]. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , the invest igator, or the ERB 
of the s tudy sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
[IP_ADDRESS]. Discontinuation of the Study
The study  will be di scontinued if Lilly or its designee judges it necessary  for m edical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87885] ical Manual o f Mental  Disorders, 5th
Edition DSM -5®. CBS Publishers and Distributors, 2017.
Bredl au AL, Harel  BT, McDerm ott MP, Dworki n RH, Korones DN, Dolan JG, Adams HR. 
Neurocognit ive changes after sustained ketamine administration in children with chronic pain . 
J Palliat Care Med . 2015;5(2): doi:10.4172/2165- 7386.1000215.
Evers S, Rahmann A, Kraemer C, Kurlemann G, Debus O, Husstedt IW, Frese A. Treatment of 
childhood migraine attacks with oral zo lmitriptan and ibuprofen. Neurology . 
2006;67 (3):497-499.
Fernandes R, Ferreira JJ, Sampaio C. The placebo response in studies of acute migraine. J 
Pediatr . 2008;152(4):527-533.
International Headache Society . The Internat ional Cl assificat ion of Headache Disorders, 3rd 
edition. Cephalalgia. 2018;38(1):1 -211. Avai lable at: https://www.ichd -3.org/wp -
content/uploads/2018/01/The -Internat ional-Classificat ion-of-Headache -Disorders -3rd-Edition-
2018.pdf .
Kato N, Takimoto H, Yokoy ama T, Yokoy a S, Tanaka T, Tada H. Updated Japanese growth 
references for infants and preschool children, based on historical, ethnic and environmental 
characterist ics. Acta Paediatr . 2014 ;103(6):e251 –e261 .
Maruff P, Thom as E, Cysique L, Brew B, Collie A, Sny der P, Pi [INVESTIGATOR_41279]. Validit y of CogState 
Brief Battery: relati onship to standardized tests and 
sensit ivityto cognitive impairment in mild 
traum atic brain injury , schizophrenia, and AIDS dementia co mplex. Arch Clin Neuropsychol . 
2009;24(2):165-178.
Mollica CM, Maruff P, Collie A, Vance A. Repeated assess ment of cognit ion in children and the 
measurement of performance change. Child Neuropsychol . 2005;11(3):303 -
310.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin 
GA, Greenhill L, Shen S, Mann JJ. The Co lumbia -Suicide Sev erity Rating Scale: init ial 
validit y and internal  consistency findings from three mult isite studies wit h adolescents and 
adults. Am J Psychiatry .2011;168(12):1266 -1277.
Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on precision criteria to derive s ample 
size when designing pediatric pharmacokinet ic studies . J Clin Pharmacol . 2012; 52(10 ):1601-
1606 .
H8H-MC-LAHX Clinical Pharmacology Protocol Page 51
LY57314412. Appendices
H8H-MC-LAHX Clinical Pharmacology Protocol Page 52
LY573144Appendix 1. Abbreviations and Definitions
Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
patient administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with t his treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally a ssociated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP alkaline phosphatase
ALT alanine aminotransferase
assent Agreement from a child or other individual who is not legal ly capable of providing consent, 
but who can understand the circumstances and potential risks involved in participating in a 
study (required by [CONTACT_80522] [IRBs]/ethical review boards [ERBs]).
AST aspartate aminotransferase
AUC areaunder the concentration -versus -time curve
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
Cmax maximum observed drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by [CONTACT_57994].  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CRF case report form
CRP Clinical Research Physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist 
(CRS), global safety physician ,or other medical officer.
CRU Clinical Research Unit
C-SSRS Columbia -Suicide Severity Rating Scale
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87886]
GCP good clini cal practice
IB Investigator’s Brochure
ICF informed consent form
ICH Intern ational Council for Harmonisation
IEC Independent Ethics Committee
informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to participate in a 
particular study, after having been informed of all aspects of the study that are relevant to 
the patient’s decision to participate.  Informed consent is documented by [CONTACT_3553] a 
written, signed, and dated informed consent form.
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical study, including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marke ted products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator A person responsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
IRB institutional review board
Legal 
RepresentativeAn individual or judicial or other body authorized under applicable law to consent, on 
behalf of a prospective patient, to the patient’s participation in the clinical study.
MedDRA Medical Dictionary for Regulatory Activities
open label A study  in which there are no restrictions on knowledge of treatment allocation ;therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PK pharmacokinetic (s)
H8H-MC-LAHX Clinical Pharmacology Protocol Page [ADDRESS_87887] of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical study .
S[LOCATION_003]R suspected unexpected serious adverse reaction
TBL total bilirubin
TEAE treatment -emergent adverse event :  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state ,anddoes not necessarily have to have a causal relationship with this 
treatment .
tmax time to reach maximum observed drug concentration
ULN upper limit of normal
H8H-MC-LAHX Clinical Pharmacology Protocol Page 55
LY573144Appendix 2. Clinical Laboratory  Tests
Clinical Laboratory Tests
HematologyaClinical Chemistrya
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Phospho rus
Leukocytes (WBC) Magnesium
Platelets Glucose (random)
Absolute counts of: Blood urea nitrogen (BUN)
Neutrophils Total protein
Lymphocy tes Albumin
Monocytes Total bilirubin
Eosinophils Direct bilirubin
Basophils Total protein
Alkaline phosphatase (ALP)
UrinalysisaAspartate aminotransferase (AST)
Specific gravity Alanine aminotransferase (ALT)
pH Uric acid
Protein Estimated glomerular filtration rate (eGFR)b
Glucose Creatinine
Ketones
Bilirubin
Urobilinogen
Blood Other Tests
Nitrite Urine drug screena
Leukocyte esterasecUrine pregnancy  testd
Urine culturecSerum pregnancy  testa
Microsopic analysiscGonadal ho rmonea(estradiol for femal es, and 
testosterone for males)
Abbreviations:  RBC = red blood cell; WBC = white blood cell.
aAssay ed by [CONTACT_3211] -designated laboratory.
bGFR calculated by [CONTACT_80523] 2009 formula or the Japanese Society for Pediatric Nephrology formula for 
patients in Japan.
cA positive urine leukocyte esterase result will require a follow -up sample with microscopic analysis and possibly
a urine culture.
dPerformed l ocally.
Note:  Additional tests may be performed at the discretion of the investigator as needed.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 56
LY573144This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .
Protocol H8H -MC -LAHX Sampling Summary
Purpose Blood Volume per 
Sample (mL)Maximum Number of Blood 
SamplesTotal Volume 
(mL)
Hematologya2 [ADDRESS_87888] volume .
cUnscheduled hepatic monitoring testing may be performed as part of patient follow -up, based on l aboratory  
safety values andin consultation with Lilly CRP/CRS.
H8H-MC-LAHX Clinical Pharmacology Protocol Page 57
LY573144Appendix 3. Liver Safety :  Sug gested A ctions and 
Follow -Up Assessments
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with Lilly Medical or its desi gnee .
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrom bin time
WBC Prothrombin time, INR
Neutrophils
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Conjugated bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST Alkaline Phosphatase Isoenzymes a
GGT
CPK Anti -smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = asp artate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red 
blood cell; WBC = white blood cell.
aAssay ed by [CONTACT_11007] -designated or central laboratory.
bReflex/con firmation dependent on regulatory requirements and/or testing availability .
Leo Document ID = d443c63b-d4f7-4e9e-841a-ea05c0a724fe
Approver: 
Approval Date & Time: 28-Mar-2019 18:18:07 GMT
Signature [CONTACT_32869]: Approved
Approver:
Approval Date & Time: 29-Mar-2019 02:36:10 GMT
Signature [CONTACT_32869]: Approved
[COMPANY_003]
[COMPANY_003]